TABLE 5.

Literature review of isavuconazole treatment in children^a

Case no.	Age (y)	Sex	Disease	Proven IFD	Pathogen	First-line therapy	Reason to switch	Salvage treatment	ISA dose (mg/day)	IFD outcome	AE	Authors (reference)
1	4.5	M	ALL	Mucormycosis (orbital sinus)	Rhizopus oryzae	L-AMB + CAS	IFD progression	L-AMB + ISA	80–160 (i.v.), 100–200 (p.o.)	CR	None	Barg et al. (15)
2	5	M	ALL	Mucormycosis (hard palate, skull, conchae)	Negative culture	L-AMB	IFD progression	L-AMB + ISA	150–200 (i.v.), 100–200 (p.o.)	CR	None	Barg et al. (15)
3	3	F	ALL	Mucormycosis (disseminated)	Lichtheimia spp.	VRC	Renal impairment	ISA monotherapy	70–180 (i.v.), 200 (p.o.)	PR	Nausea, vomiting	Cornu et al. (16)
4	13.8	NI	HM	Mucormycosis		L-AMB	IFD progression	L-AMB + ISA	4 mg/kg/day (i.v.-p.o.)	CR	None	Muggeo et al. (14)
5	16	NI	HM	Mucormycosis		L-AMB	Maintenance therapy	ISA monotherapy	4 mg/kg/day (p.o.)	CR	None	Muggeo et al. (14)
6	7	F	ALL	Mucormycosis	Cunninghamella	ABLC + CAS	IFD progression	ABLC + ISA + CAS	200–400 (i.v.-p.o.)	CR	None	Pomorska et al. (17)

^aAbbreviations: AE, adverse events; ALL, acute lymphoblastic leukemia; CR, complete resolution; F, female; HM, hematologic malignancy; i.v., intravenous; M, male; NI, not indicated; p.o., oral; PR, partial resolution.